Human Papillomavirus (HPV)- Epidemiology Forecast to 2028

Date: January 1, 2019
Pages: 50
Price:
US$ 3,250.00
License [?]:
Publisher: DelveInsight
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: H300955282CEN
Leaflet:

Download PDF Leaflet

Human Papillomavirus (HPV)- Epidemiology Forecast to 2028
This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Human Papillomavirus (HPV) - Epidemiology Forecast, 2028' report provides a comprehensive analysis of the Human Papillomavirus (HPV) epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

MARKETS COVERED
  • United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2016-2028

Human Papillomavirus (HPV) Epidemiology

The epidemiology section covers the historical, current as well as forecasted epidemiology for Human Papillomavirus (HPV) in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Human Papillomavirus (HPV) outlook. It also includes the explanation of changing trends of epidemiology outlining the Human Papillomavirus (HPV) scenario.
Human Papillomavirus (HPV) Epidemiology Segmentation

The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Human Papillomavirus (HPV) thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

REPORT SCOPE
  • The report covers detailed overview of Human Papillomavirus (HPV) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
  • The Human Papillomavirus (HPV) Report assesses the disease risk and burden and highlights the unmet needs
  • It also helps to recognize the growth opportunities in the 7MM with respect to the patient population
Key strengths
  • 10 Year Forecast
  • 7MM Coverage
  • Total Cases in Human Papillomavirus (HPV)
Key assessments
  • Patient Segmentation in Human Papillomavirus (HPV)
  • Human Papillomavirus (HPV) Risk & Burden
  • Factors driving growth in a specific Human Papillomavirus (HPV) patient population
1. REPORT INTRODUCTION

2. HUMAN PAPILLOMAVIRUS (HPV) EPIDEMIOLOGY OVERVIEW AT A GLANCE

2.1. Patient Share Distribution of Human Papillomavirus (HPV) in 2016
2.2. Patient Share Distribution of Human Papillomavirus (HPV) in 2028

3. DISEASE BACKGROUND AND OVERVIEW: HUMAN PAPILLOMAVIRUS (HPV)

3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment

4. EPIDEMIOLOGY AND PATIENT POPULATION

4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Human Papillomavirus (HPV) in 7MM
4.3. Total Prevalent/ Incident Patient Population of Human Papillomavirus (HPV) in 7MM – By Countries

5. EPIDEMIOLOGY OF HUMAN PAPILLOMAVIRUS (HPV) BY COUNTRIES

5.1. United States
  5.1.1. Assumptions and Rationale
  5.1.2. Prevalent/Incident Cases of the Human Papillomavirus (HPV)
  5.1.3. Sub-Type Specific cases of the Human Papillomavirus (HPV)
  5.1.4. Sex- Specific Cases of the Human Papillomavirus (HPV)
  5.1.5. Diagnosed Cases of the Human Papillomavirus (HPV)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
  5.4.1. Assumptions and Rationale
  5.4.2. Prevalent/Incident Cases of the Human Papillomavirus (HPV)
  5.4.3. Sub-Type Specific cases of the Human Papillomavirus (HPV)
  5.4.4. Sex- Specific Cases of the Human Papillomavirus (HPV)
  5.4.5. Diagnosed Cases of the Human Papillomavirus (HPV)
5.5. France
  5.5.1. Assumptions and Rationale
  5.5.2. Prevalent/Incident Cases of the Human Papillomavirus (HPV)
  5.5.3. Sub-Type Specific cases of the Human Papillomavirus (HPV)
  5.5.4. Sex- Specific Cases of the Human Papillomavirus (HPV)
  5.5.5. Diagnosed Cases of the Human Papillomavirus (HPV)
5.6. Italy
  5.6.1. Assumptions and Rationale
  5.6.2. Prevalent/Incident Cases of the Human Papillomavirus (HPV)
  5.6.3. Sub-Type Specific cases of the Human Papillomavirus (HPV)
  5.6.4. Sex- Specific Cases of the Human Papillomavirus (HPV)
  5.6.5. Diagnosed Cases of the Human Papillomavirus (HPV)
5.7. Spain
  5.7.1. Assumptions and Rationale
  5.7.2. Prevalent/Incident Cases of the Human Papillomavirus (HPV)
  5.7.3. Sub-Type Specific cases of the Human Papillomavirus (HPV)
  5.7.4. Sex- Specific Cases of the Human Papillomavirus (HPV)
  5.7.5. Diagnosed Cases of the Human Papillomavirus (HPV)
5.8. United Kingdom
  5.8.1. Assumptions and Rationale
  5.8.2. Prevalent/Incident Cases of the Human Papillomavirus (HPV)
  5.8.3. Sub-Type Specific cases of the Human Papillomavirus (HPV)
  5.8.4. Sex- Specific Cases of the Human Papillomavirus (HPV)
  5.8.5. Diagnosed Cases of the Human Papillomavirus (HPV)
5.9. Japan
  5.9.1. Assumptions and Rationale
  5.9.2. Prevalent/Incident Cases of the Human Papillomavirus (HPV)
  5.9.3. Sub-Type Specific cases of the Human Papillomavirus (HPV)
  5.9.4. Sex- Specific Cases of the Human Papillomavirus (HPV)
  5.9.5. Diagnosed Cases of the Human Papillomavirus (HPV)

6. UNMET NEEDS OF THE HUMAN PAPILLOMAVIRUS (HPV)

7. APPENDIX

8. REPORT METHODOLOGY

8.1. Sources

9. DELVEINSIGHT CAPABILITIES

10. DISCLAIMER

11. ABOUT DELVEINSIGHT

Indication Specific


LIST OF TABLES

Table 1: Total Prevalent/Incident Cases of the Human Papillomavirus (HPV) in 7MM
Table 2: Total Prevalent/Incident Cases of the Human Papillomavirus (HPV) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Human Papillomavirus (HPV) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Human Papillomavirus (HPV) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Human Papillomavirus (HPV) in United States (2016-2028)
Table 6: Diagnosed Cases of the Human Papillomavirus (HPV) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Human Papillomavirus (HPV) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Human Papillomavirus (HPV) in Germany (2016-2028)
Table 9: Sex- Specific Cases of the Human Papillomavirus (HPV) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Human Papillomavirus (HPV) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Human Papillomavirus (HPV) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Human Papillomavirus (HPV) in France (2016-2028)
Table 13: Sex- Specific Cases of the Human Papillomavirus (HPV) in France (2016-2028)
Table 14: Diagnosed Cases of the Human Papillomavirus (HPV) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Human Papillomavirus (HPV) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Human Papillomavirus (HPV) in Italy (2016-2028)
Table 17: Sex- Specific Cases of the Human Papillomavirus (HPV) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Human Papillomavirus (HPV) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Human Papillomavirus (HPV) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Human Papillomavirus (HPV) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Human Papillomavirus (HPV) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Human Papillomavirus (HPV) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Human Papillomavirus (HPV) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Human Papillomavirus (HPV) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Human Papillomavirus (HPV) in UK (2016-2028)
Table 26: Diagnosed Cases of the Human Papillomavirus (HPV) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Human Papillomavirus (HPV) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Human Papillomavirus (HPV) in Japan (2016-2028)
Table 29: Sex- Specific Cases of the Human Papillomavirus (HPV) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Human Papillomavirus (HPV) in Japan (2016-2028)

LIST OF FIGURES

Figure 1: Total Prevalent/Incident Cases of the Human Papillomavirus (HPV) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Human Papillomavirus (HPV) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Human Papillomavirus (HPV) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Human Papillomavirus (HPV) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Human Papillomavirus (HPV) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Human Papillomavirus (HPV) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Human Papillomavirus (HPV) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Human Papillomavirus (HPV) in Germany (2016-2028)
Figure 9: Sex- Specific Cases of the Human Papillomavirus (HPV) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Human Papillomavirus (HPV) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Human Papillomavirus (HPV) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Human Papillomavirus (HPV) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Human Papillomavirus (HPV) in France (2016-2028)
Figure 14: Diagnosed Cases of the Human Papillomavirus (HPV) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Human Papillomavirus (HPV) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Human Papillomavirus (HPV) in Italy (2016-2028)
Figure 17: Sex- Specific Cases of the Human Papillomavirus (HPV) in Italy (2016-2028)
Figure 18: Diagnosed Cases of the Human Papillomavirus (HPV) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Human Papillomavirus (HPV) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Human Papillomavirus (HPV) in Spain (2016-2028)
Figure 21: Sex- Specific Cases of the Human Papillomavirus (HPV) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Human Papillomavirus (HPV) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Human Papillomavirus (HPV) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Human Papillomavirus (HPV) in UK (2016-2028)
Figure 25: Sex- Specific Cases of the Human Papillomavirus (HPV) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Human Papillomavirus (HPV) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Human Papillomavirus (HPV) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Human Papillomavirus (HPV) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Human Papillomavirus (HPV) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Human Papillomavirus (HPV) in Japan (2016-2028)
Skip to top


Ask Your Question

Human Papillomavirus (HPV)- Epidemiology Forecast to 2028
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: